The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections

Emerging Microbes and Infections

Volumn 3, Issue , 2014, Pages

  Egli, Adrian ^a   Santer, Deanna M ^b   O'Shea, Daire ^b,c   Tyrrell, D Lorne ^b   Houghton, Michael ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

B cells; Hepatitis C virus; Immune response; Innate immunity; Interferon lambda; Receptor; Respiratory viruses; T cells

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA RECEPTOR ALPHA; INTERFERON LAMBDA3; INTERFERON LAMBDA4; INTERFERON RECEPTOR; LIGAND; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS VACCINE; ALPHA INTERFERON RECEPTOR; ANTIVIRUS AGENT; CYTOKINE; GAMMA INTERFERON; INTERFERON 3; INTERFERON LAMBDA 3; INTERFERON LAMBDA 4; INTERFERON STIMULATED GENE FACTOR; INTERLEUKIN 28A; INTERLEUKIN 29;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; DENDRITIC CELL; FEEDBACK SYSTEM; GENE EXPRESSION; GENETIC ASSOCIATION; HELPER CELL; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN INDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH1 TH2 BALANCE; TH2 CELL; VIRUS INFECTION; VIRUS RESISTANCE; ACUTE HEPATITIS C; ANTIVIRAL THERAPY; B LYMPHOCYTE; CHRONIC HEPATITIS C; EVIDENCE BASED PRACTICE; GENE EXPRESSION REGULATION; LYMPHOCYTE PROLIFERATION; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR BINDING; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS IMMUNITY;

HEPATITIS C VIRUS;

EID: 84903779440     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.51     Document Type: Article

References (169)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267
2. Kotenko SV, Langer JA. Full house: 12 receptors for 27 cytokines. Int Immunopharmacol 2004; 4: 593-608 (Pubitemid 38559077)
3. Allen G, Fantes KH. A family of structural genes for human lymphoblastoid (leukocytetype) interferon. Nature 1980; 287: 408-411 (Pubitemid 11250347)
4. Seto MH, Harkins RN, Adler M, Whitlow M, Church WB, Croze E. Homology model of human interferon-alpha 8 and its receptor complex. Protein Sci 1995; 4: 655-670
5. Streuli M, Nagata S, Weissmann C. At least three human type alpha interferons: structure of alpha 2. Science 1980; 209: 1343-1347 (Pubitemid 11181461)
6. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. The crystal structure of human interferon beta at 2.2-A resolution. Proc Natl Acad Sci USA 1997; 94: 11813-11818
7. Senda T, Shimazu T, Matsuda S et al. Three-dimensional crystal structure of recombinant murine interferon-beta. EMBO J 1992; 11: 3193-3201
8. Ealick SE, Cook WJ, Vijay-Kumar S et al. Three-dimensional structure of recombinant human interferon-gamma. Science 1991; 252: 698-702 (Pubitemid 21916995)
9. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77 (Pubitemid 36109115)
10. Sheppard P, Kindsvogel W, XuWet al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68 (Pubitemid 36104710)
11. Gad HH, Hamming OJ, Hartmann R. The structure of human interferon lambda and what it has taught us. J Interferon Cytokine Res 2010; 30: 565-571
12. Kumaran J, Wei L, Kotra LP, Fish EN. A structural basis for interferon-alpha-receptor interactions. FASEB J 2007; 21: 3288-3296
13. Fasler-Kan E, Pansky A, Wiederkehr M, Battegay M, Heim MH. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem 1998; 254: 514-519 (Pubitemid 28308101)
14. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon alpha activates multiple STAT proteins and upregulates proliferation-associated IL- 2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999; 93: 1980-1991 (Pubitemid 29128500)
15. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-568 (Pubitemid 351913674)
16. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002; 296: 1653-1655 (Pubitemid 34579157)
17. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12: 125-135
18. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386 (Pubitemid 40685987)
19. Blouin CM, Lamaze C. Interferon gamma receptor: the beginning of the journey. Front Immunol 2013; 4: 267
20. Hamming OJ, Terczynska-Dyla E, Vieyres G et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013; 32: 3055-3065
21. Prokunina-Olsson L, Muchmore B, TangWet al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171
22. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002; 13: 223-240 (Pubitemid 34693176)
23. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555-564
24. Fox BA, Sheppard PO, O'Hara PJ. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS ONE 2009; 4: e4933
25. Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko SV, Wlodawer A. Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferonlambdaR1. J Mol Biol 2010; 404: 650-664
26. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345
27. Hillyer P, Mane VP, Schramm LM et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 2012; 90: 774-783
28. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferonlambda3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125-131
29. Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of Type I and Type III Interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 2014; 59: 1262-1272
30. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, beta, and lambda interferons by the NS1andNS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol 2004; 78: 4363-4369 (Pubitemid 38437240)
31. Ioannidis I, Ye F, McNally B, Willette M, Flano E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol 2013; 87: 3261-3270
32. Ank N, WestH, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509
33. Coccia EM, SeveraM, Giacomini E et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805 (Pubitemid 39255927)
34. Langhans B, Kupfer B, Braunschweiger I et al. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-865
35. Diegelmann J, Beigel F, Zitzmann K et al. Comparative analysis of the lambdainterferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 2010; 5: e15200
36. MihmS, FreseM, Meier V et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004; 84: 1148-1159 (Pubitemid 39128260)
37. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008; 8: 911-922
38. Stoltz M, Klingstrom J. Alpha/beta interferon (IFN-alpha/beta)- independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection. J Virology 2010; 84: 9140-9148
39. Ank N, Iversen MB, Bartholdy C et al. An important role for type III interferon (IFNlambda/ IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-2485
40. Hou W, Wang X, Ye L et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 2009; 83: 3834-3842
41. Chandra PK, Bao L, Song K et al. HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol 2014; 184: 214-229
42. Sheahan T, Morrison TE, Funkhouser W et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 2008; 4: e1000240
43. Khaitov MR, Laza-Stanca V, Edwards MR et al. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 2009; 64: 375-386
44. Jewell NA, Cline T, Mertz SE et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 2010; 84: 11515-11522
45. WolkK,Witte K, Witte E et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83: 1181-1193
46. Yin Z, Dai J, Deng J et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 2012; 189: 2735-2745
47. Lauterbach H, Bathke B, Gilles S et al. Mouse CD8alpha1 DCs and human BDCA31 DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 2010; 207: 2703-2717
48. Megjugorac NJ, Gallagher GE, Gallagher G. IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood 2010; 115: 4185-4190
49. Egli A, Levin A, Santer DM et al. Immunomodulatory function of interleukin-28B during primary infection with Cytomegalovirus. J Infect Dis; e-pub ahead of print 8 April 2014. doi: 10.1093/infdis/jiu144
50. McFadden G, Mohamed MR, Rahman MM, Bartee E. Cytokine determinants of viral tropism. Nat Rev Immunol 2009; 9: 645-655
51. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002; 2: 675-687 (Pubitemid 37328725)
52. Dankar SK, Miranda E, Forbes NE et al. Influenza A/Hong Kong/156/1997(H5N1) virus NS1 gene mutations F103L and M106I both increase IFN antagonism, virulence and cytoplasmic localization but differ in binding to RIG-I and CPSF30. Virol J 2013; 10: 243
53. Tumpey TM, Szretter KJ, van Hoeven N et al. The Mx1 gene protectsmice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol 2007; 81: 10818-10821 (Pubitemid 47463355)
54. Yang Y, Zhang L, Geng H et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 2013; 4: 951-961
55. Dai J, Megjugorac NJ, Amrute SB, Fitzgerald-Bocarsly P. Regulation of IFN regulatory factor-7 and IFN-alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. J Immunol 2004; 173: 1535-1548 (Pubitemid 38971583)
56. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Molecular Cell 1998; 1: 507-518 (Pubitemid 128374687)
57. Onoguchi K, Yoneyama M, Takemura A et al. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007; 282: 7576- 7581 (Pubitemid 47093699)
58. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007; 179: 3434-3442
59. Thomson SJ, Goh FG, Banks H et al. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc Natl Acad Sci USA 2009; 106: 11564-11569
60. Genin P, Vaccaro A, Civas A. The role of differential expression of human interferon - a genes in antiviral immunity. Cytokine Growth Factor Rev 2009; 20: 283-295
61. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25: 349- 360 (Pubitemid 44354220)
62. Lee HC, Narayanan S, Park SJ, Seong SY, Hahn YS. Transcriptional regulation of IFNlambda genes in hepatitis C virus-infected hepatocytes via IRF-3.IRF-7.NF-kappaB complex. J Biol Chem 2014; 289: 5310-5319
63. Griffiths SJ, Koegl M, Boutell C et al. A systematic analysis of host factors reveals a Med23-interferon-lambda regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog 2013; 9: e1003514
64. Duggal P, Thio CL, Wojcik GL et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 2013; 158: 235-245
65. Bibert S, Roger T, Calandra T et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116
66. Chinnaswamy S, Chatterjee S, Boopathi R, Mukherjee S, Bhattacharjee S, Kundu TK. A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-kappaB-mediated gene transcription. PLoS ONE 2013; 8: e75495
67. Fischer J, Bohm S, ScholzMet al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55: 1700-1710
68. Smith KR, Suppiah V, O'Connor K et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011; 3: 57
69. de Castellarnau M, Aparicio E, Parera M et al. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS ONE 2012; 7: e31016
70. McFarland AP, Horner SM, Jarret A et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15: 72-79
71. Honda M, Shirasaki T, Shimakami T et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin 28B genotypes. Hepatology 2014; 59: 828-838
72. Dill MT, Duong FH, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031
73. Rallon NI, Soriano V, Naggie S et al. Impact of IL28B gene polymorphisms on interferon-lambda3 plasma levels during pegylated interferon-alpha/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J Antimicrob Chemother 2012; 67: 1246-1249
74. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109
75. Shi X, Pan Y, Wang M et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS ONE 2012; 7: e37054
76. Haralambieva IH, Ovsyannikova IG, Kennedy RB et al. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 2011; 29: 7883-7895
77. Jimenez-Sousa MA, Berenguer J, Fernandez-Rodriguez A et al. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients. J Viral Hepat 2014; 21: 189-197
78. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104
79. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferonlambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009; 284: 20869-20875
80. Reboul J, Gardiner K, Monneron D, Uze G, Lutfalla G. Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster. Genome Res 1999; 9: 242-250 (Pubitemid 29168187)
81. Josephson K, Logsdon NJ, Walter MR. Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 2001; 15: 35-46 (Pubitemid 32728318)
82. Magracheva E, Pletnev S, Kotenko S, Li W, Wlodawer A, Zdanov A. Purification, crystallization and preliminary crystallographic studies of the complex of interferonlambda1 with its receptor. Acta Crystallogr Sect F Struct Biol Cryst Commun 2010; 66: 61-63
83. Yoon SI, Jones BC, Logsdon NJ et al. Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure 2010; 18: 638-648
84. Witte K, Gruetz G, Volk HD et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009 10: 702-714
85. Brand S, Beigel F, Olszak T et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: G960-G968 (Pubitemid 41532589)
86. Doyle SE, Schreckhise H, Khuu-Duong K et al. Interleukin-29 uses a type 1 interferonlike program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906 (Pubitemid 46489554)
87. Maher SG, Sheikh F, Scarzello AJ et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-1115
88. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 2003; 370: 391-396 (Pubitemid 36315126)
89. Yang L, Luo Y,Wei J, He S. Integrative genomic analyses on IL28RA, the common receptor of interferon-lambda1, -lambda2 and -lambda3. Int J Mol Med 2010; 25: 807-812
90. Liu BS, Janssen HL, Boonstra A. IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 2011; 117: 2385-2395
91. Duong FH, Trincucci G, Boldanova T et al. IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med 2014; 211: 857-868
92. Kohli A, Zhang X, Yang J et al. Distinct and overlapping genomic profiles and antiviral effects of interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cells. J Viral Hepat 2012; 19: 843-853
93. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854 (Pubitemid 40327973)
94. Wang Y, Li J, Wang X et al. Hepatitis C virus impairs TLR3 signaling and inhibits IFNlambda 1 expression in human hepatoma cell line. Innate Immun 2014; 20: 3-11
95. Sedger LM. microRNA control of interferons and interferon induced anti-viral activity. Mol Immunol 2013; 56: 781-793
96. Jimenez-Sousa MA, Berenguer J, Rallon N et al. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/ HCV-coinfected patients. J Viral Hepat 2013; 20: 358-366
97. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985-990
98. Li Y, Cheng H, Zuo XB et al. Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population. J Med Genet 2013; 50: 812-818
99. Malhotra S,Morcillo-Suarez C, Brassat D et al. IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. J Neuroimmunol 2011; 239: 101-104
100. Lopez de Lapuente A, Alloza I, Goertsches R et al. Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. J Neuroimmunol 2012; 245: 98-101
101. Vandenbroeck K, Alvarez J, Swaminathan B et al. A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes Immun 2012; 13: 21-28
102. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 2008; 283: 32925-32936
103. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011; 60: 1284-1293
104. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269-32274 (Pubitemid 39014676)
105. Steed A, Buch T, Waisman A, Virgin HW 4th. Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. J Virol 2007; 81: 6134-6140 (Pubitemid 46847051)
106. Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFNgamma signaling - does it mean JAK-STAT? Cytokine Growth Factor Rev 2008; 19: 383-394
107. Kearney S, Delgado C, Lenz LL. Differential effects of type I and II interferons on myeloid cells and resistance to intracellular bacterial infections. Immunol Res 2013; 55: 187-200
108. Malakhova OA, Kim KI, Luo JK et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006; 25: 2358-2367 (Pubitemid 44012219)
109. Mordstein M, Kochs G, Dumoutier L et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 2008; 4: e1000151
110. Mordstein M, Neugebauer E, Ditt V et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010; 84: 5670-5677
111. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898 (Pubitemid 44958521)
112. Mahlakoiv T, Ritz D, Mordstein M et al. Combined action of type I and type III interferon restricts initial replication of SARS-Coronavirus in the lung but fails to inhibit systemic virus spread. J Gen Virol 2012; 93: 2601-2605
113. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-465 (Pubitemid 46834848)
114. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8: 837-848
115. Thomas E, Gonzalez VD, Li Q et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978-988
116. Jilg N, LinW, Hong J et al. Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and IL28B are altered by infection with hepatitis C virus. Hepatology 2014; 59: 1250-1261
117. Younossi ZM, Birerdinc A, EstepM, StepanovaM, Afendy A, Baranova A. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Transl Med 2012; 10: 25
118. Sarasin-Filipowicz M, Wang X, Yan M et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009; 29: 4841-4851
119. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B et al. USP18- based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS ONE 2011; 6: e22200
120. Dill MT, Makowska Z, Duong FH et al. Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012; 143: 777-786
121. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039 (Pubitemid 351754525)
122. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15: 31-33
123. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509
124. Abe H, Hayes CN, Ochi H et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83: 1597-1607
125. Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444 (Pubitemid 40712193)
126. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563 (Pubitemid 350155537)
127. Lau DT, Negash A, Chen J et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013; 144: 402-413
128. Manry J, Laval G, Patin E et al. Evolutionary genetic dissection of human interferons. J Exp Med 2011; 208: 2747-2759
129. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401
130. Uehata T, Akira S. mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/ MCPIP-1. Biochim Biophys Acta 2013; 1829: 708-713
131. Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896
132. Maekawa S, Sakamoto M, Miura M et al. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to peginterferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology 2012; 56: 1611-1621
133. Gullberg E, Cao S, Berg OG et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 2011; 7: e1002158
134. Morishima C, Polyak SJ, Ray R et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis 2006; 193: 931-940
135. Sarrazin C, Mihm U, Herrmann E et al. Clinical significance of in vitro replicationenhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. J Infect Dis 2005; 192: 1710-1719 (Pubitemid 41587820)
136. Rousseau CM, Daniels MG, Carlson JM et al. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 2008; 82: 6434-6446 (Pubitemid 351875121)
137. Rentenaar RJ, Gamadia LE, van DerHoek N et al. Development of virus-specific CD41 T cells during primary cytomegalovirus infection. J Clin Invest 2000; 105: 541-548 (Pubitemid 30127255)
138. Duarte-Rojo A, Veldt BJ, Goldstein DD et al. The course of posttransplant hepatitis c infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 94: 197-203
139. Cisneros E, Banos I, Citores M et al. Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 2012; 94: 275-280
140. Russell CD, Griffiths SJ, Haas J. Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg? DNA Cell Biol 2014; 33: 60-63
141. Trevino A, Lopez M, Vispo E et al. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis 2012; 55: e1-e4
142. Kamihira S, Usui T, Ichikawa T et al. Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and coinfection with hepatitis C virus. Virol J 2012; 9: 40
143. Bravo D, Solano C, Gimenez E et al. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 2013; 86: 838-844
144. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969
145. Gunthner R, Anders HJ. Interferon-regulatory factors determine macrophage phenotype polarization. Mediators Inflamm 2013; 2013: 731023
146. Novak ML, Koh TJ. Macrophage phenotypes during tissue repair. J Leukoc Biol 2013; 93: 875-881
147. van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol 2013; 31: 317-343
148. Kohu K, Ohmori H, Wong WF et al. The Runx3 transcription factor augments Th1 and down-modulates Th2 phenotypes by interacting with and attenuating GATA3. J Immunol 2009; 183: 7817-7824
149. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006; 107: 4417-4423 (Pubitemid 43801368)
150. CroftM. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9: 271-285
151. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711 (Pubitemid 37174545)
152. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7: 179-190
153. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000; 14: 1693-1711 (Pubitemid 30602989)
154. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313-319 (Pubitemid 26132509)
155. Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE. Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. J Immunol 2001; 166: 7276-7281 (Pubitemid 32525602)
156. Zhu J, Min B, Hu-Li J et al. Conditional deletion of Gata3 shows its essential function in TH1-TH2 responses. Nat Immunol 2004; 5: 1157-1165 (Pubitemid 39549630)
157. Lohoff M, Mak TW. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 2005; 5: 125-135 (Pubitemid 40208902)
158. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009; 113: 5829-5838
159. Jordan WJ, Eskdale J, Srinivas S et al. Human interferon lambda-1 (IFN-lambda1/IL- 29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254-261 (Pubitemid 46679436)
160. Koltsida O, Hausding M, Stavropoulos A et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011; 3: 348-361
161. Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G. Interferonlambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008; 125: 492-502
162. Gallagher G, Megjugorac NJ, Yu RY et al. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res 2010; 30: 603-615
163. Bullens DM, Decraene A, Dilissen E et al. Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy 2008; 38: 1459-1467
164. Edwards MR, Johnston SL. Deficient interferon in virus-induced asthma exacerbations. Clin Exp Allergy 2008; 38: 1416-1418
165. Baraldo S, Contoli M, Bazzan E et al. Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. J Allergy Clin Immunol 2012; 130: 1307-1314
166. Contoli M, Message SD, Laza-Stanca V et al. Role of deficient type III interferon lambda production in asthma exacerbations. Nat Med 2006; 12: 1023-1026 (Pubitemid 44353382)
167. Russell CD, Griffiths SJ, Haas J. Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg? DNA Cell Biol 2014; 33: 60-63
168. Chi B, Dickensheets HL, Spann KM et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 2006; 80: 5032-5040
169. Hummelshoj L, Ryder LP, Poulsen LK. The role of the interleukin-10 subfamilymembers in immunoglobulin production by human B cells. Scand J Immunol 2006; 64: 40-47 (Pubitemid 44195101)